Aclaris Therapeutics

Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company's lead drug candidate, A-101 Topical Solution, is a high-concentration hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK), a non-malignant skin tumor. The Company has completed over three Phase II clinical trials of A-101 in over 300 patients with SK. The Company has initiated a Phase II clinical trial of A-101 for the treatment of common warts. In addition to A-101, the Company is also developing A-102, a topical gel dosage form of hydrogen peroxide, for the treatment of both SK and common warts. It has in-licensed the rights to inhibitors of the Janus kinase (JAK) family of enzymes, for specified dermatological conditions.
Malvern, US
Size (employees)
18 (est)
Aclaris Therapeutics was founded in 2012 and is headquartered in Malvern, US

Aclaris Therapeutics Office Locations

Aclaris Therapeutics has office in Malvern
Malvern, US

Aclaris Therapeutics Metrics

Aclaris Therapeutics Summary

Market capitalization

$611 m

Closing share price

Aclaris Therapeutics's current market capitalization is $611 m.

Aclaris Therapeutics Market Value History

We estimate that Aclaris Therapeutics's current employees are approximately 28% female and 72% male.

Aclaris Therapeutics News

Aclaris Therapeutics Company Life

You may also be interested in